EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications

Anna Sofie Buhl Rasmussen, Cecilie Utke Rank, Ib Jarle Christensen, Allan Weimann, Kasper Hansen, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Hilde Skuterud Wik, Hartmut Vogt, Ulrika Norén-Nyström, Goda Vaitkeviciene und 6 weitere

Cancer Chemotherapy and Pharmacology · 19.06.2026 · 96 (1)

DOI: 10.1007/s00280-026-04914-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 19.06.2026. Verfasst von Anna Sofie Buhl Rasmussen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Imatinib Mesylate, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Tyrosine kinase inhibitors (TKIs) have improved outcomes in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and are increasingly incorporated into treatment protocols of Philadelphia chromosome-like (Ph-like, ABL-class) ALL. However, central nervous system (CNS) relapse remains a significant challenge. Imatinib, a first-generation TKI, demonstrates limited CNS penetration in adults, yet data in children are sparse.

Methods

This prospective, multicenter study investigated cerebrospinal fluid (CSF) and matched plasma concentrations of imatinib and its primary bioactive metabolite (N-desmethyl-imatinib) in children and young adults with Ph + or Ph-like (ABL-class) ALL. Plasma and CSF samples were analyzed with liquid chromatography tandem mass spectrometry (LC-MS/MS). Linear mixed-effects models were used to assess concentrations across compartments and over time.

Results

Between January 2023 and June 2025, 32 paired plasma and CSF samples were collected from ten patients (range 1–8 samples/patient; median: 3). In total, 78% of plasma imatinib concentrations were above 1,000 ng/mL. On average, plasma imatinib concentrations were 189-fold higher than in CSF (geometric mean ratio, 95% CI: 142–249, p < 0.001), which was even more profound for N-desmethyl-imatinib (geometric mean ratio 273, 95% CI: 218–339, p < 0.001). The highest measured CSF-imatinib concentration was 63 ng/mL. During therapy, both plasma and CSF imatinib concentrations declined at an average of 0.32% per day ( p < 0.001), resulting in stable CSF-to-plasma ratio over a median follow-up of 5.7 months (range: 0–14 months).

Conclusion

The very low CSF concentrations support the rationale for alternative TKIs with improved CNS distribution in patients at risk of CNS relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylatePrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsAntineoplastic AgentsCentral Nervous SystemHumansMaleFemaleChildAdolescentProspective StudiesYoung AdultChild, PreschoolTandem Mass SpectrometryAdultChromatography, LiquidTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaCentral nervous systemCerebrospinal fluidImatinibPediatricYoung adults

Substanzen

Imatinib MesylateProtein Kinase InhibitorsAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.
  • Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Molecular Unit, Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Haematology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Department of Biomedical and Clinical Science, Linköping University, Linköping, Sweden.

Förderung

  • National Hospital

Zitieren

APA

Rasmussen, A. S. B., Rank, C. U., Christensen, I. J., Weimann, A., Hansen, K., Thastrup, M., Yang, T., Lund, T. M., Wik, H. S., Vogt, H., Norén-Nyström, U., Vaitkeviciene, G., Albertsen, B. K., Wehner, P. S., Als-Nielsen, B., Andersen, C. L., Dalhoff, K., & Schmiegelow, K. (2026). Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04914-9

Vancouver

Rasmussen ASB, Rank CU, Christensen IJ, Weimann A, Hansen K, Thastrup M, et al. Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04914-9

BibTeX
@article{Rasmussen2026,
  author = {Rasmussen, Anna Sofie Buhl and Rank, Cecilie Utke and Christensen, Ib Jarle and Weimann, Allan and Hansen, Kasper and Thastrup, Maria and Yang, Tianwu and Lund, Trine Meldgaard and Wik, Hilde Skuterud and Vogt, Hartmut and Norén-Nyström, Ulrika and Vaitkeviciene, Goda and Albertsen, Birgitte Klug and Wehner, Peder Skov and Als-Nielsen, Bodil and Andersen, Christen Lykkegaard and Dalhoff, Kim and Schmiegelow, Kjeld},
  title = {Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04914-9}
}
Kostenlos starten →